The biological dependence of BCMA signaling on MM cell is known, but it is more commonly used as a pan-MM surface marker for targeted delivery of cytotoxic therapeutics (Tai and Anderson, 2019). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.